The application of CRISPR/Cas9–based genome-wide screening to disease research
Open Access
- 21 December 2024
- journal article
- research article
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 79, 102004
Abstract
No abstract availableKeywords
This publication has 161 references indexed in Scilit:
- Advances in targeting cancer epigenetics using CRISPR-dCas9 technology: A comprehensive review and future prospectsFunctional & Integrative Genomics, 2024
- Current progress in CRISPR–Cas systems for cancer2024
- A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatmentFunctional & Integrative Genomics, 2023
- Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast CancerAdvanced Science, 2023
- CRISPR-Cas13 technology portfolio and alliance with other genetic toolsBiotechnology Advances, 2022
- Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genesClinical and Translational Medicine, 2022
- Identification of ERCC8 as a novel cisplatin-resistant gene in esophageal cancer based on genome-scale CRISPR/Cas9 screeningBiochemical and Biophysical Research Communications, 2022
- Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatmentAdvanced Drug Delivery Reviews, 2021
- Innovative Precision Gene‐Editing Tools in Personalized Cancer MedicineAdvanced Science, 2020
- Innate immunity to adenovirus: lessons from miceFEBS Letters, 2019